연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
2045. A point mutation in the heavy chain complementarity-determining region 3 (HCDR3) significantly enhances the specificity of an anti-ROS1 antibody
Lee HK, Jin J, Kim SI, Kang MJ, Yi EC, Kim JE, Park JB, Kim H, Chung J
Biochem Biophys Res Commun. 2017 Nov 4;493(1):325-331. doi: 10.1016/j.bbrc.2017.09.023. Epub 2017 Sep 6.
Link
2044. Preclinical development of a humanized neutralizing antibody targeting HGF.
Kim H, Hong SH, Kim JY, Kim IC, Park YW, Lee SJ, Song SW, Kim JJ, Park G, Kim TM, Kim YH, Park JB, Chung J, Kim IH.
Exp Mol Med. 2017 Mar 24;49(3):e309. doi: 10.1038/emm.2017.21.
Link
2043. Discrepancy Between Tumor Antigen Distribution and Radiolabeled Antibody Binding in a Nude Mouse Xenograft Model of Human Melanoma.
Kim YI, Paeng JC, Cheon GJ, Kang KW, Lee DS, Chung JK
Cancer Biother Radiopharm. 2017 Apr;32(3):83-89. doi: 10.1089/cbr.2016.2115. Epub 2017 Apr 5.
Link
2042. Preclinical anaylses of [18F]cEFQ as a PET tracer for imaging metabotropic glutamate receptor type 1 (mGluR1).
Lee B, Kim YK, Lee JY, Kim YJ, Lee YS, Lee DS, Chung JK, Jeong JM
J Cereb Blood Flow Metab. 2017 Jun;37(6):2283-2293. doi: 10.1177/0271678X16663948. Epub 2016 Jan 1.
Link
2041. Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.
Kim S, Koh J, Kwon D, Keam B, Go H, Kim YA, Jeon YK, Chung DH
Eur J Cancer. 2017 Apr;75:141-149. doi: 10.1016/j.ejca.2017.01.004. Epub 2017 Feb 20.
Link
2040. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.
Koh J, Kim S, Kim MY, Go H, Jeon YK, Chung DH
Oncotarget. 2017 Feb 21;8(8):13762-13769. doi: 10.18632/oncotarget.14632.
Link
2039. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D, Koh J, Kim S, Go H, Kim YA, Keam B, Kim TM, Kim DW, Jeon YK, Chung DH.
Lung Cancer. 2017 Apr;106:131-137. doi: 10.1016/j.lungcan.2017.02.008. Epub 2017 Feb 16.
Link
2038. Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy.
Cho N, Im SA, Cheon GJ, Park IA, Lee KH, Kim TY, Kim YS, Kwon BR, Lee JM, Suh HY, Suh KJ
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):328-339. doi: 10.1007/s00259-017-3849-3. Epub 2017 Nov 4.
Link
2037. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ, Min A, Im SA, Jang H, Lee KH, Lau A, Lee M, Kim S, Yang Y, Kim J, Kim TY, Oh DY, Brown J, O`Connor MJ, Bang YJ
Int J Cancer. 2017 Jan 1;140(1):109-119
Link
2036. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Park YH, Im SA, Kim SB, Sohn JH, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim JY, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH; Korean Cancer Study Group (KCSG)
Eur J Cancer. 2017 Nov;86:385-393
Link